Literature DB >> 31618079

microRNA-451a prevents activation of matrix metalloproteinases 2 and 9 in human cardiomyocytes during pathological stress stimulation.

Nathan Robert Scrimgeour1,2, Aleksandra Wrobel1,2, Maria João Pinho1,2, Morten Andre Høydal1,2.   

Abstract

Matrix metalloproteinases (MMP) are important for cardiac remodeling. Recently, microRNA (miR)-451a has been found to inhibit the expression of both MMP-2 and MMP-9 in human malignancies, but its role in cardiomyocytes has not been explored. We hypothesized that miR-451a modulates MMP-2 and MMP-9 levels in human cardiomyocytes. The role of miR-451a on regulation of MMP-2 and MMP-9 was evaluated in two separate pathological models using Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs): 1) endothelin-1 (ET-1), and 2) 48-h hypoxia (1% O2). Both models were transfected with synthetic miR-451a mimics or scramble control. Expression of both mRNA and miR was determined by quantitative real-time polymerase chain reaction and protein activity by (MMP-2/9) activity assay. Bioinformatic analyses were performed using Targetscan 7.1 and STRING 10.5. hiPS-CMs stimulated by hypoxia increased both MMP-2 and MMP-9 expression levels compared with normoxia (P < 0.05), whereas ET-1 stimulation only increased the MMP-9 level compared with vehicle controls (P < 0.05). miR-451a mimics prevented the increase of MMP-2 and MMP-9 expression in both models. Protein activity of MMP-2 and MMP-9 was confirmed to be lower following treatment with miR-451a mimic compared with scramble-controls. Six of 28 predicted gene transcripts of miR-451a were linked to MMP-2 and MMP-9; Macrophage migration inhibitory factor (MIF) was the only predicted target of miR-451a that was increased by ET-1 and hypoxia and reduced following miR-451a mimic transfection. miR-451a prevent the increase of MMP-2 and MMP-9 in human cardiomyocytes during pathological stress. The modulation by miR-451a on MMP-2 and MMP-9 is caused by MIF.

Entities:  

Keywords:  cardiomyocytes; matrix metalloproteinases; microRNA

Mesh:

Substances:

Year:  2019        PMID: 31618079     DOI: 10.1152/ajpcell.00204.2019

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  6 in total

1.  MicroRNA-451a attenuates angiotensin II-induced cardiac fibrosis and inflammation by directly targeting T-box1.

Authors:  Hao-Yuan Deng; Ze-Yin He; Zhi-Chao Dong; Yun-Long Zhang; Xiao Han; Hui-Hua Li
Journal:  J Physiol Biochem       Date:  2021-12-01       Impact factor: 4.158

2.  An Integrated Metabolomic Screening Platform Discovers the Potential Biomarkers of Ischemic Stroke and Reveals the Protective Effect and Mechanism of Folic Acid.

Authors:  Yan-Hui Yang; Lei Lei; Yin-Ping Bao; Lu Zhang
Journal:  Front Mol Biosci       Date:  2022-05-18

3.  MicroRNA Profiling of HL-1 Cardiac Cells-Derived Extracellular Vesicles.

Authors:  Serena Silvestro; Agnese Gugliandolo; Luigi Chiricosta; Francesca Diomede; Oriana Trubiani; Placido Bramanti; Jacopo Pizzicannella; Emanuela Mazzon
Journal:  Cells       Date:  2021-01-30       Impact factor: 6.600

4.  Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy.

Authors:  Maria Lombardi; Davide Lazzeroni; Giulia Benedetti; Gloria Bertoli; Dejan Lazarevic; Michela Riba; Francesco De Cobelli; Ornella Rimoldi; Giulia d'Amati; Iacopo Olivotto; Chiara Foglieni; Paolo Camici
Journal:  Clin Transl Med       Date:  2021-07

5.  Mesenchymal stem cell-derived exosomes protect trabecular meshwork from oxidative stress.

Authors:  Ying-Chao Li; Juan Zheng; Xi-Zi Wang; Xin Wang; Wen-Jing Liu; Jian-Lu Gao
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

6.  Circulating whole genome miRNA expression corresponds to progressive right ventricle enlargement and systolic dysfunction in adults with tetralogy of Fallot.

Authors:  Chad S Weldy; Saad Ali Syed; Myriam Amsallem; Dong-Qing Hu; Xuhuai Ji; Rajesh Punn; Anne Taylor; Brittany Navarre; Sushma Reddy
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.